Spore Briefing Weekly: 2026-10-19 – 2026-10-25
Spore Briefing Weekly: 2026-10-19 – 2026-10-25
TLDR
- Psilocybin may help with depression through brain pathways but needs more long-term study.
- Ketamine-assisted psychotherapy may speed recovery in treatment-resistant depression, but results are mixed.
- Fractal patterns in the brain may hint at shared psychiatric conditions, but not yet used for diagnosis.
- Psychedelics and hypnosis may lead to similar altered states, but the benefits are still unclear.
- Beware of overhyped claims about functional mushrooms and natural treatments.
Biggest Study of the Week
A 2026 systematic review in Europe PMC titled “Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment” provides a detailed look at how psilocybin might work in treating depression. The study points to several biological pathways, including activation of the 5-HT2A receptor and changes in brain connectivity. It also suggests that psilocybin may be as effective as escitalopram in some cases. But the review is clear: the evidence is still early, and long-term effects and risks are not well understood. Read more
Most Overhyped Headline
The headline “From Altered States to Fundamental Peace: Taxonomies of Consciousness, Psychedelics and Hypnosis Through the Lens of the Yoga Vāsiṣṭha” from OpenAlex tries to tie together psychedelics, hypnosis, and ancient philosophy in a sweeping way. The paper is well-researched, but it stretches its conclusions. It suggests that these altered states may lead to “fundamental peace” without enough clinical evidence to back it up. The review is theoretical and lacks experimental data on long-term outcomes. Read more
Functional Mushroom Watch
A 2026 review in Europe PMC titled “Safety and Efficacy of Natural and Conventional Psychiatric Treatments” looks at mushroom-derived compounds like Hericium erinaceus and their potential in mental health. The review says some natural compounds show promise, but human clinical trials are missing. It also warns about risks like intoxication and drug interactions. Read more
Psychedelic Research Watch
A systematic review in Europe PMC titled “Subacute and long-term changes in cognitive functioning after administration of classic psychedelics, MDMA and ketamine” found that psilocybin had the most consistent evidence of cognitive improvement, particularly in flexibility and attention. But the study also points out that many of the included trials had methodological flaws, and more rigorous research is needed. Read more
Clinical Trial Watch
An exploratory trial of ketamine-assisted psychotherapy (KAP) combined with subcutaneous esketamine in treatment-resistant depression found short-term benefits. The KAP group had lower depression scores and higher remission rates. But a six-month follow-up found no significant differences between groups. The study’s non-randomized design makes it hard to draw firm conclusions. Read more
DMT / Consciousness Watch
A systematic review on fractal analysis in psychiatric neuroimaging found consistent fractal patterns in the frontal cortex across multiple disorders. This suggests shared brain abnormalities, but the review does not say these patterns are ready for use in diagnosis. More research is needed to standardize the method. Read more
Don’t Get Scammed
A review of natural treatments in mental health warns that many mushroom-derived compounds and medicinal plants lack robust clinical evidence. The review says these substances may pose safety risks and should not be used as standalone treatments without further research and medical supervision. Read more
Best Content Opportunities
- “Psilocybin and the Brain: What the Science Actually Says” – A short video explaining the mechanisms of psilocybin in depression and the limitations of current research.
- “Fractals in the Mind: A Visual Guide to Brain Patterns in Mental Illness” – A visually engaging piece using fractal analysis to explain brain imaging in psychiatry.
- “Ketamine-Assisted Therapy: Real Results or Hype?” – A short-form debate on the efficacy and risks of KAP based on recent trials.
- “Functional Mushrooms: Myths vs. Reality” – A debunking video highlighting the overhyped claims around medicinal mushrooms and current scientific evidence.
Sources
- Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment (Europe PMC)
- From Altered States to Fundamental Peace (OpenAlex)
- Subacute and long-term changes in cognitive functioning (Europe PMC)
- Exploratory non-randomized clinical trial of subcutaneous esketamine (Europe PMC)
- Complexity in disguise: a systematic review of fractal analysis (Europe PMC)
- Safety and Efficacy of Natural and Conventional Psychiatric Treatments (Europe PMC)
- A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study (Europe PMC)
- Psychedelic-assisted psychotherapy: Emerging paradigm (Europe PMC)
Final Takeaway
This week’s research shows both the promise and the gaps in psychedelic and natural treatments for mental health. Psilocybin may help with depression, but the evidence is still limited in scope and long-term clarity. Ketamine-assisted therapy can offer faster relief, but follow-up data is sparse. Fractal analysis in neuroimaging is intriguing but not yet a clinical tool. As always, the media and public must be cautious of overhyped claims, especially when they skip the step of long-term clinical trials. The field is moving forward, but it needs more rigorous, independent research and better communication of what is known—and what is not.
Educational Disclaimer
This article is for informational and educational purposes only. It is not
medical advice, mental health advice, diagnosis, treatment guidance, or a
recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may
suggest. Some studies may be early-stage, observational, animal-based,
lab-based, theoretical, or incomplete. Always consult a qualified
professional before making health-related decisions.
If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.
